Glaxosmithkline Share News (GSK)

LONDON MARKET CLOSE: UK Shares Dragged Down By Commodity Weakness

How Wellcome and Gates charities profit from helping biotech

* Wellcome firm gets approval for cancer imaging agent * First product from Wellcome Trust in two decades * Follows $80 mln biotech windfall for Gates foundation By Ben Hirschler LONDON, May 30 (Reuters) - The Wellcome Trust medical charity is to profit from U.S. approval

New incentives needed to develop antibiotics to fight superbugs

(Repeats May 27 story with no changes) By Bill Berkrot NEW YORK, May 27 (Reuters) - Drugmakers are renewing efforts to develop medicines to fight emerging antibiotic-resistant bacteria, but creating new classes of drugs on the scale needed is unlikely to happen without new financial

New incentives needed to develop antibiotics to fight superbugs

By Bill Berkrot NEW YORK, May 27 (Reuters) - Drugmakers are renewing efforts to develop medicines to fight emerging antibiotic-resistant bacteria, but creating new classes of drugs on the scale needed is unlikely to happen without new financial incentives to make the effort worth the inves

CORRECTED-UPDATE 3-U.S. sees first case of bacteria resistant to last-resort antibiotic

(Corrects headline, first and third paragraphs to show bacteria is resistant to last-resort antibiotic colistin, not all antibiotics) By Ransdell Pierson and Bill Berkrot May 26 (Reuters) - U.S. health officials on Thursday reported the first case in the country of a patient with an i

GSK gets EU approval for first gene therapy for children

LONDON, May 27 (Reuters) - The world's first life-saving gene therapy for children, developed by GlaxoSmithKline and Italian scientists, was approved for sale in Europe on Friday, in a step forward for the pioneering technology to fix faulty genes. Called Strimvelis, it is designed for a t

Glaxo's Strimvelix Gene Therapy Gets European Marketing Authorisation

UPDATE 1-G7 told to act on antibiotics as dreaded superbug hits U.S.

* Cameron urges G7 to back reward system for new drugs * U.S. sees first case of resistance to last-resort drug * Antimicrobial resistance moving up political agenda (Adds details on problem in U.S., China and Europe) By Kylie MacLellan and Ben Hirschler ISE-SHIMA, Japan

China regulator to launch drug pricing probe in June

SHANGHAI, May 27 (Reuters) - China will carry out wide-ranging pricing inspections on drug firms, hospitals and procurement bodies from June 1, the country's top watchdog said on Friday, extending a tough cost-cutting campaign to reduce the price of healthcare. The National Development and

UPDATE 1-Novartis willing to sell Roche stake without demanding premium - CEO

(Releads with CEO comments on Roche stake) ZURICH, May 25 (Reuters) - Swiss drugmaker Novartis is ready to sell its near $14 billion stake in rival Roche without demanding a premium, Chief Executive Joe Jimenez said on Wednesday. Novartis has been discussing options with banks for s

GlaxoSmithKline Reports Long-Term Data For Gene Therapy In ADA-SCID

BROKER RATINGS SUMMARY: Shore Says Buy Shire, Hold GlaxoSmithKline

Britain's Serious Fraud Office re-examines funding model

By Kirstin Ridley LONDON, May 24 (Reuters) - The Serious Fraud Office (SFO), Britain's leading fraud and corruption investigator and prosecutor, said on Tuesday it was re-examining a funding model that has been criticised for risking weakening investigations and delaying cases. So-cal

UPDATE 1-GSK lung drug succeeds in big UK study, after earlier miss

* Salford COPD study success follows failure of 2015 trial * 8.4 pct reduction in exacerbations vs standard care (Adds comment from GSK executive and analyst) By Ben Hirschler LONDON, May 24 (Reuters) - GlaxoSmithKline's new inhaled medicine Breo proved significantly better th

GlaxoSmithKline announces positive results from Relvar Ellipta study

(ShareCast News) - GlaxoSmithKline and Innovia announced positive headline results from their Salford lung study of Relvar Ellipta in the treatment of chronic obstructive pulmonary disease (COPD). The study showed Relvar Ellipta achieved a superior reduction in exacerbations versus usual care in pat